

Remarks

Claims 1-23 have been canceled and replaced with new claim 24. Support for new claim 24 can be found throughout the specification and original claim 15. More specifically, support for new claim 24 can be found in Example 1 on page 7 of the specification. Example 1 describes an *in vitro* test showing a synergistic effect between topotecan and imatinib and complete reversal of BCRP-mediated resistance to topotecan in those cells.

Election/Restriction

New claim 24 is most similar to the invention described in Group II. Therefore, Applicants wish to provisionally elect without traverse Group II, which was original claim 15. Claim 24 defines osteosarcoma as the cancer to be treated and the anti-cancer agents as imatinib or a pharmaceutically acceptable salt thereof, preferably the mesylate salt. Applicants believe claim 24 defines the species. Entry of this Response is respectfully requested.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7852

  
\_\_\_\_\_  
Oona A. Manzari  
Attorney for Applicants  
Reg. No. 48,152

Date: 12/19/07